<DOC>
	<DOCNO>NCT00866346</DOCNO>
	<brief_summary>Primary Objective : To determine maximally tolerate dose donor PR1-specific cytotoxic T-lymphocytes ( PR1-CTL ) treatment relapse persistent chronic myelogenous leukemia ( CML ) allogeneic hematopoietic transplantation HLA-matched relate unrelated donor . Secondary Objectives : 1 . To evaluate immunological response follow PR1-CTL treatment 2 . To evaluate clinical efficacy determine clinical , cytogenetic molecular response rate within 6 month</brief_summary>
	<brief_title>PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia ( CML ) After Allogeneic Hematopoietic Transplantation</brief_title>
	<detailed_description>Before treatment start , complete physical exam , include blood ( 2 tablespoon ) test . You chest x-ray bone marrow collect . To collect bone marrow sample , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . Women able child must negative blood pregnancy test . You treat donor immune cell ( T lymphocytes ) specifically target certain leukemia cell body . Each participant receive two dos donor cell , 60 day apart . The second dose give 60 day first dose , high dose level , long serious side effect occur first dose still disease present . Four dose level PR1-specific T lymphocytes consider . Up 30 patient treat cohort 3 , start low dose level , skip untried dose level escalate . The trial stop early low dose level find unacceptably toxic . These cell give outpatient basis . After donor cell infusion , follow week outpatient clinic least 1 month every 3 month least one year . You routine blood ( 2 tablespoon ) urine test visit . Participants experience side effect leukemia leukemia treatment may need hospitalize earlier . You also receive several medication help decrease risk infection immune system weak . These include preventative antibiotic , antiviral drug , antifungal drug . Bone marrow sample take second cell infusion , 8 week , 12 week , 6 month 1 year second cell infusion . This investigational study . A total 30 patient take part study . All enrol UTMDACC .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>1 . Patients chronic myelogenous leukemia ( CML ) previously undergone allogeneic hematopoietic transplantation evidence disease , define , b c ( ) &gt; 5 % Philadelphia chromosome positive cell cytogenetic study &gt; /= 3 month posttransplant 2 . ( b ) For patient cytogenetic remission posttransplant , molecular evidence disease time , define recurrence quantitative PCR positivity bcrabl achieve molecular remission confirm 2 assay , 3 month apart sooner clinically indicate ; OR &gt; 10fold increase relative expression bcrabl/abl detect confirmed minimum 2 consecutive PCR analysis , 3 month apart sooner 3 . ( c ) Molecular evidence persistent disease Real time PCR ( bcrabl/ abl x 100 0.05 decline ) &gt; 3 month posttransplantation treatment imatinib mesylate . 4 . Patients must HLA compatible relate unrelated donor capable donate peripheral blood stem cell use apheresis technique . This must donor use original allogeneic hematopoetic transplantation . Patient must HLAA2 positive 5 . ECOG performance status &lt; = 2 6 . Serum bilirubin &lt; = 2 mg/dl 7 . Serum transaminases &lt; 4 x normal 8 . Serum creatinine &lt; = 2 mg/dl 9 . No active uncontrolled infection 10 . HIV negative 11 . No acute and/or chronic GVHD require systemic steroid therapy 12 . Patient pregnant breast feeding . 13 . Signed informed consent 14 . Patients must immunosuppressive medication least 2 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Allogeneic Hematopoietic Transplantation</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>PR1-Specific Cytotoxic T-Lymphocyte Infusion</keyword>
</DOC>